These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33246453)

  • 1. Impact of co-payment level increase of antidiabetic medications on glycaemic control: an interrupted time-series study among Finnish patients with type 2 diabetes.
    Lavikainen P; Aarnio E; Jalkanen K; Tirkkonen H; Rautiainen P; Laatikainen T; Martikainen J
    BMC Health Serv Res; 2020 Nov; 20(1):1095. PubMed ID: 33246453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contacting dropouts from type 2 diabetes care in public primary health care: description of the patient population.
    Kauppila T; Laine MK; Honkasalo M; Raina M; Eriksson JG
    Scand J Prim Health Care; 2016 Sep; 34(3):267-73. PubMed ID: 27404014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 2 diabetes medication and HbA1c levels in North Karelia Finland, 2013-2019.
    Wikström K; Lamidi ML; Rautiainen P; Tirkkonen H; Laatikainen T
    Diabet Med; 2022 Sep; 39(9):e14866. PubMed ID: 35506179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in clinical characteristics, medication use, and glycemic control in insulin-treated patients with type 1 and type 2 diabetes in Finland in 2012-2019: Nationwide real-world evidence study.
    Niskanen L; Hannula M; Kysenius K; Kaijala S; Lassenius MI; Valle TT
    J Diabetes; 2024 May; 16(5):e13491. PubMed ID: 38273701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of a co-payment increase on the consumption of type 2 antidiabetics - A nationwide interrupted time series analysis.
    Rättö H; Kurko T; Martikainen JE; Aaltonen K
    Health Policy; 2021 Sep; 125(9):1166-1172. PubMed ID: 34078544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
    Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.
    Heald AH; Livingston M; Malipatil N; Becher M; Craig J; Stedman M; Fryer AA
    Diabetes Obes Metab; 2018 Jan; 20(1):185-194. PubMed ID: 28730750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term impact of co-payment level increase on the use of medication and patient-reported outcomes in Finnish patients with type 2 diabetes.
    Lavikainen P; Aarnio E; Niskanen L; Mäntyselkä P; Martikainen J
    Health Policy; 2020 Dec; 124(12):1310-1316. PubMed ID: 32878700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ANALYSIS OF ANTIDIABETIC THERAPY FOR TYPE 2 DIABETES IN PRIMARY HEALTH CARE (WESTERN KAZAKHSTAN).
    Bazargaliyev Y; Tleumagamabetova B; Kudabayeva K; Kosmuratova R
    Georgian Med News; 2024 Mar; (348):22-27. PubMed ID: 38807384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cost reduction of routine medications following a residential programme combining physical activity and nutrition in the treatment of type 2 diabetes: a prospective cohort study.
    Lanhers C; Walther G; Chapier R; Lesourd B; Naughton G; Pereira B; Duclos M; Vinet A; Obert P; Courteix D; Dutheil F
    BMJ Open; 2017 Apr; 7(4):e013763. PubMed ID: 28416496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK.
    Lind M; Pivodic A; Cea-Soriano L; Nerman O; Pehrsson NG; Garcia-Rodriguez LA
    Diabetologia; 2014 Aug; 57(8):1586-94. PubMed ID: 24811709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: A retrospective UK cohort study.
    Jude EB; Trescoli C; Emral R; Ali A; Lubwama R; Palmer K; Shaunik A; Nanda N; Raskin P; Gomez-Peralta F
    Diabetes Obes Metab; 2021 Apr; 23(4):929-937. PubMed ID: 33319424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex differences and correlates of poor glycaemic control in type 2 diabetes: a cross-sectional study in Brazil and Venezuela.
    G Duarte F; da Silva Moreira S; Almeida MDCC; de Souza Teles CA; Andrade CS; Reingold AL; Moreira ED
    BMJ Open; 2019 Mar; 9(3):e023401. PubMed ID: 30842107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O; Shaw JE; Blonde L; Paul SK
    Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes.
    Kim K; Unni S; Brixner DI; Thomas SM; Olsen CJ; Sterling KL; Mitchell M; McAdam-Marx C
    Diabetes Obes Metab; 2019 Jul; 21(7):1725-1733. PubMed ID: 30848039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between number of contacts between previous dropouts with type 2 diabetes and health care professionals on glycaemic control: A cohort study in public primary health care.
    Kauppila T; Eriksson JG; Honkasalo M; Raina M; Laine MK
    Prim Care Diabetes; 2019 Oct; 13(5):468-473. PubMed ID: 30928432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes.
    Ghouse J; Isaksen JL; Skov MW; Lind B; Svendsen JH; Kanters JK; Olesen MS; Holst AG; Nielsen JB
    Diabetes Obes Metab; 2020 Feb; 22(2):231-242. PubMed ID: 31596048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
    Rodbard HW; Tripathy D; Vidrio Velázquez M; Demissie M; Tamer SC; Piletič M
    Diabetes Obes Metab; 2017 Oct; 19(10):1389-1396. PubMed ID: 28345792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.